Alnylam’s gene-silencing therapy for a rare kidney disorder met the main goal of a late-stage study, bringing the company a step closer to marketing the first approved treatment for the condition.
https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png00Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2019-12-17 07:04:102019-12-17 07:04:10Alnylam gene-silencing therapy to treat kidney disorder succeeds in late-stage study
